[
  {
    "ts": null,
    "headline": "Pfizer : Political Action Committee (PAC) Report January 2023 - December 2024",
    "summary": "Pﬁzer PAC Leading the Conversation. Pﬁzer PAC and Corporate Political ...",
    "url": "https://finnhub.io/api/news?id=181a4ee8d5242d4a82b074fd1b58259ce42091c376cb1e307498503b4213831c",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745259718,
      "headline": "Pfizer : Political Action Committee (PAC) Report January 2023 - December 2024",
      "id": 134028026,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "Pﬁzer PAC Leading the Conversation. Pﬁzer PAC and Corporate Political ...",
      "url": "https://finnhub.io/api/news?id=181a4ee8d5242d4a82b074fd1b58259ce42091c376cb1e307498503b4213831c"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. (PFE): One of the Safe Dividend Stocks with Yields Above 5%",
    "summary": "We recently published a list of the 10 Safe Dividend Stocks with Yields Above 5%. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other safe dividend stocks. Dividend-paying stocks have long held a special place among investors, often delivering stronger returns than the broader market over time. […]",
    "url": "https://finnhub.io/api/news?id=fe624d7574b5645197e06cd6968c487a13e10a7466c970e7fb92327b437fc357",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745245151,
      "headline": "Pfizer Inc. (PFE): One of the Safe Dividend Stocks with Yields Above 5%",
      "id": 134022908,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "We recently published a list of the 10 Safe Dividend Stocks with Yields Above 5%. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other safe dividend stocks. Dividend-paying stocks have long held a special place among investors, often delivering stronger returns than the broader market over time. […]",
      "url": "https://finnhub.io/api/news?id=fe624d7574b5645197e06cd6968c487a13e10a7466c970e7fb92327b437fc357"
    }
  },
  {
    "ts": null,
    "headline": "How To Build A $500,000 Dividend Portfolio That Could Yield 18.35% In 20 Years",
    "summary": "How To Build A $500,000 Dividend Portfolio That Could Yield 18.35% In 20 Years",
    "url": "https://finnhub.io/api/news?id=8e6e3fa32e40da513514f0f565d1f27638b2825a954a29a44461dbeec46ac129",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745244000,
      "headline": "How To Build A $500,000 Dividend Portfolio That Could Yield 18.35% In 20 Years",
      "id": 134025125,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=8e6e3fa32e40da513514f0f565d1f27638b2825a954a29a44461dbeec46ac129"
    }
  },
  {
    "ts": null,
    "headline": "How a scrapped Pfizer drug became a winner for SpringWorks",
    "summary": "SpringWorks Therapeutics and the Children’s Tumor Foundation salvaged a shelved asset for neurofibromatosis and got it over the regulatory finish line.",
    "url": "https://finnhub.io/api/news?id=19589934ec076a78f8ecaba729871c88671dfb77822973efb1b1774242b51018",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745222400,
      "headline": "How a scrapped Pfizer drug became a winner for SpringWorks",
      "id": 134022909,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "SpringWorks Therapeutics and the Children’s Tumor Foundation salvaged a shelved asset for neurofibromatosis and got it over the regulatory finish line.",
      "url": "https://finnhub.io/api/news?id=19589934ec076a78f8ecaba729871c88671dfb77822973efb1b1774242b51018"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: Is The Dividend Yield Worth The Effort?",
    "summary": "Pfizer: Is The Dividend Yield Worth The Effort?",
    "url": "https://finnhub.io/api/news?id=82f53c0273c9c4dc477014b9202e26deffdb14c83207b5fd9a288c5e8a09e15f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745207728,
      "headline": "Pfizer: Is The Dividend Yield Worth The Effort?",
      "id": 134020223,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=82f53c0273c9c4dc477014b9202e26deffdb14c83207b5fd9a288c5e8a09e15f"
    }
  },
  {
    "ts": null,
    "headline": "How To Put $100 In Your Retirement Fund Each Month With Pfizer Stock",
    "summary": "Pfizer (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the U.S. and internationally. It will report its Q1 2025 earnings on April 29. Wall Street analysts expect the company to post EPS of $0.70, down from $0.82 in the prior-year period. According to data from Benzinga Pro, quarterly revenue is expected to be $14.27 billion, down from $14.88 billion a year earlier. The 52-week range of Pfizer stock price was $20.92 to $31.54. Pfizer's d",
    "url": "https://finnhub.io/api/news?id=f8a65613087a57ef9303d1ef00d3e7ff81fd367cc039ab759493205c751f8160",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745200859,
      "headline": "How To Put $100 In Your Retirement Fund Each Month With Pfizer Stock",
      "id": 134022910,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the U.S. and internationally. It will report its Q1 2025 earnings on April 29. Wall Street analysts expect the company to post EPS of $0.70, down from $0.82 in the prior-year period. According to data from Benzinga Pro, quarterly revenue is expected to be $14.27 billion, down from $14.88 billion a year earlier. The 52-week range of Pfizer stock price was $20.92 to $31.54. Pfizer's d",
      "url": "https://finnhub.io/api/news?id=f8a65613087a57ef9303d1ef00d3e7ff81fd367cc039ab759493205c751f8160"
    }
  }
]